School of Pharmaceutical Sciences, Jaipur National University, Jaipur 302025, Rajasthan, India.
Eur J Med Chem. 2011 Apr;46(4):1006-18. doi: 10.1016/j.ejmech.2011.01.009. Epub 2011 Jan 15.
Thirty new 2-(substituted)-3-{[substituted]amino}quinazolin-4(3H)-one were designed and synthesized keeping in view the structural requirement of pharmacophore and evaluated for anticonvulsant activity and neurotoxicity. The anticonvulsant activity of the titled compounds was assessed using the 6 Hz psychomotor seizure test. The most active compound of the series was 3-({(E)-[3-(4-chloro-3-methylphenoxy)phenyl]methylidene}amino)-2-phenylquinazolin-4(3H)-one PhQZ 7, which showed 100% protection (4/4, 0.5 h) and 75% protection (3/4, 0.25 h) at a dose of 100 mg/kg in mice. A computational study was carried out for calculation of pharmacophore pattern and prediction of pharmacokinetic properties. Titled compounds have also exhibited good binding properties with epilepsy molecular targets such as glutamate, GABA (A) delta and GABA (A) alpha-1 receptors, in Lamarckian genetic algorithm based flexible docking studies.
基于药效团的结构要求,设计并合成了 30 个新的 2-(取代)-3-{[取代]氨基}喹唑啉-4(3H)-酮,并评估了它们的抗惊厥活性和神经毒性。使用 6 Hz 运动性癫痫发作试验评估标题化合物的抗惊厥活性。该系列中最活跃的化合物是 3-({[(E)-[3-(4-氯-3-甲基苯氧基)苯基]亚甲基}氨基)-2-苯基喹唑啉-4(3H)-酮 PhQZ7,在 100mg/kg 剂量下,在小鼠中分别显示 100%(4/4,0.5 h)和 75%(3/4,0.25 h)的保护作用。进行了计算研究,以计算药效团模式并预测药代动力学性质。在基于 Lamarckian 遗传算法的柔性对接研究中,标题化合物还表现出与癫痫分子靶标(如谷氨酸、GABA(A)δ和 GABA(A)α-1 受体)的良好结合特性。